Roche's ($RHHBY) new melanoma drug Zelboraf apparently works even better than researchers suspected. Approved by FDA via its fast-track program, the targeted therapy demonstrated early on it improved survival time for patients with BRAF-positive melanoma. However, newly published trial data highlight median overall survival of almost 16 months, compared with 6 to 10 months for the typical patient with metastatic disease. Story